Intermittently Scanned CGM Positively Impacts Glycemic Control in Diabetics
By HospiMedica International staff writers Posted on 13 Jan 2020 |
Image: The Freestyle Libre isCGM monitor (Photo courtesy of Abbot)
People with type 1 diabetes (T1D) who use intermittently scanned continuous glucose monitoring (isCGM) devices report higher treatment satisfaction, quality of life (QOL), and less severe hypoglycemia, according to a new study.
Researchers at Katholieke Universiteit Leuven (KU; Belgium), the University of Antwerp (Belgium), and other institutions conducted a 12-month prospective observational study to investigate the impact of isCGM on QOL and glycemic control in 1,913 adults with T1D who were consecutively recruited in three specialist diabetes centers in Belgium. The primary end point was evolution of QOL from baseline to 12 months, with secondary outcomes including change in hemoglobin A1C (HbA1c), time spent in different glycemic ranges, acute diabetes complications, and work absenteeism.
The results showed that HbA1c levels remained stable, as did the participants general and diabetes-specific QOL; treatment satisfaction improved during the study period. While rare, admissions for severe hypoglycemia and/or ketoacidosis decreased, reports of severe hypoglycemic events fell (14.6% versus 7.8%), as did hypoglycemic comas (2.7% versus 1.1%). Absences from work fell by 50%, but 11% of study participants experienced adverse skin reactions, leading to about one percent stopping isCGM. The study was published on December 24, 2019, in Diabetes Care.
“In 2016, nationwide reimbursement of intermittently scanned continuous glucose monitoring for people living with type one diabetes treated in specialist diabetes centers was introduced in Belgium,” concluded lead author Sara Charleer, MSc, of KU, and colleagues. “Unrestricted reimbursement results in higher treatment satisfaction, less severe hypoglycemia, and less work absenteeism, while maintaining quality of life and HbA1c.”
The isCGM device used for the study was the Abbott (Abbott Park, IL, USA) Freestyle Libre system, which continuously samples and measures interstitial glucose levels; a new glucose value is generated each minute. The sensor can provide glucose values for 14 days if the patient scans at least every 8 hours. If not, the glucose information from the previous 8-hour period will be overwritten and will not available for therapy decision-making or for later download. Unlike real time CGM devices, the Libre is factory-calibrated, which eliminates the need for daily calibration with fingerstick testing.
Related Links:
Katholieke Universiteit Leuven
University of Antwerp
Abbott
Researchers at Katholieke Universiteit Leuven (KU; Belgium), the University of Antwerp (Belgium), and other institutions conducted a 12-month prospective observational study to investigate the impact of isCGM on QOL and glycemic control in 1,913 adults with T1D who were consecutively recruited in three specialist diabetes centers in Belgium. The primary end point was evolution of QOL from baseline to 12 months, with secondary outcomes including change in hemoglobin A1C (HbA1c), time spent in different glycemic ranges, acute diabetes complications, and work absenteeism.
The results showed that HbA1c levels remained stable, as did the participants general and diabetes-specific QOL; treatment satisfaction improved during the study period. While rare, admissions for severe hypoglycemia and/or ketoacidosis decreased, reports of severe hypoglycemic events fell (14.6% versus 7.8%), as did hypoglycemic comas (2.7% versus 1.1%). Absences from work fell by 50%, but 11% of study participants experienced adverse skin reactions, leading to about one percent stopping isCGM. The study was published on December 24, 2019, in Diabetes Care.
“In 2016, nationwide reimbursement of intermittently scanned continuous glucose monitoring for people living with type one diabetes treated in specialist diabetes centers was introduced in Belgium,” concluded lead author Sara Charleer, MSc, of KU, and colleagues. “Unrestricted reimbursement results in higher treatment satisfaction, less severe hypoglycemia, and less work absenteeism, while maintaining quality of life and HbA1c.”
The isCGM device used for the study was the Abbott (Abbott Park, IL, USA) Freestyle Libre system, which continuously samples and measures interstitial glucose levels; a new glucose value is generated each minute. The sensor can provide glucose values for 14 days if the patient scans at least every 8 hours. If not, the glucose information from the previous 8-hour period will be overwritten and will not available for therapy decision-making or for later download. Unlike real time CGM devices, the Libre is factory-calibrated, which eliminates the need for daily calibration with fingerstick testing.
Related Links:
Katholieke Universiteit Leuven
University of Antwerp
Abbott
Latest Critical Care News
- AI Can Prioritize Emergecny Department Patients Requiring Urgent Treatment
- AI to Improve Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease